Oxford Biomedica’s LentiVector® platform enables the successful development of breakthrough gene and cell-based medicines.

We have a long and broad clinical and commercial track record in the gene therapy field spanning 22 years. Our data demonstrates over seven years of stable, dose dependent gene expression in patients after direct in vivo administration. Several hundreds of patients have now received ex vivo and in vivo treatment with therapies that use our vectors.

Our LentiVector® platform has delivered the first FDA and EMA approved CAR-T cell therapy.

Oxford Biomedica plc / June 2019 / Page 1 of 2
An integrated technology platform

Our partners have access to our LentiVector® platform that includes a class leading suite of technologies to improve efficiency, scalability and quality of vector production. These proprietary manufacturing technologies can also be licensed independently.

Our LentiVector® platform is widely recognised as a leading solution in gene therapy and it is the world’s first available FDA approved commercial supply of lentiviral vectors.

Advantages of lentiviral vectors over other vectors, such as AAV

— Deliver large therapeutic payloads (up to 10kb) into target cells.
— Provide permanent modification of dividing and non-dividing cells
— No pre-existing immunity of lentiviral vectors makes the platform safe

Our LentiVector® platform is designed to give the highest safety, quality and efficacy

Our vectors are optimised and well-characterised, with quality attributes that satisfy international regulatory expectations, and are known by key regulatory authorities. Our “minimal” lentiviral vectors have key safety features, such as self-inactivating LTRs, mutated WPRE and codon optimised Gag/Pol to minimise the risk of recombination.

Continuous innovation

We continuously innovate to improve our LentiVector® platform by;

— Engineering our proprietary cell lines and vectors to improve bioprocessing yield
— Developing new analytical methods to increase efficiency and quality
— Investing in automation and state-of-the-art manufacturing technologies, such as a serum-free suspension bioreactor processes
— Using in silico design tools and machine learning to drive development and innovation
— Collaborating with innovative companies to integrate cutting-edge technologies into the LentiVector® platform

We have a long and broad clinical and commercial track record in the gene therapy field.

1st

First in the world to administer lentiviral vector gene therapy directly in vivo to patients
First approved advanced therapy in the US and Europe using our platform
First commercial supplier of lentiviral vector in the world

Licensing Terms

We license our patents and know-how to our partners, giving them access to unique proprietary technologies which they use to develop their products.

Our licensing structure offers considerable flexibility to our partners, including the right to carry out tech transfer of the process to their facilities under certain conditions.

Intellectual Property

Protected by extensive know-how and multiple patent families covering vector technologies and manufacturing processes

For more information please contact:

Oxford Biomedica plc
+44 (0) 1865 783 000
www.oxb.com
partnering@oxb.com